Results 71 to 80 of about 9,531 (127)

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. [PDF]

Cancer Cell Int, 2023
Bell HL, Blair HJ, Singh M, Moorman AV, Heidenreich O, van Delft FW, Lunec J, Irving JAE.   +7 more
europepmc   +1 more source

A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers. [PDF]

Int J Gynecol Cancer, 2023
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese JL, Girda E, Miller RW, Croke J, Mackay H, Lee YC, Bowering V, Ramsahai J, Wang L, D'Souza A, Kunos CA, Oza AM, Lheureux S.   +15 more
europepmc   +1 more source

Regulation of cell size and Wee1 kinase by elevated levels of the cell cycle regulatory protein kinase Cdr2. [PDF]

J Biol Chem, 2023
Berg RA, Moseley JB.
europepmc   +1 more source

Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy. [PDF]

Int J Mol Sci, 2021
Esposito F, Giuffrida R, Raciti G, Puglisi C, Forte S.   +4 more
europepmc   +1 more source

WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response

Nature Communications
The WEE1 kinase negatively regulates CDK1/2 to control DNA replication and mitotic entry. Genetic factors that determine sensitivity to WEE1 inhibitors (WEE1i) are largely unknown.
Rinskje B. Tjeerdsma, Timothy F. Ng, Maurits Roorda, Daniëlle Bianchi, Sora Yang, Clara Bonnet, Michael VanInsberghe, Marieke Everts, Femke J. Bakker, H. Rudolf de Boer, Nathalie Moatti, Nicole Hustedt, Jay Z Yin, Lisa Hoeg, Matthew Leibovitch, Frank Sicheri, Alexander van Oudenaarden, Steven de Jong, Jeroen van den Berg, Marvin E. Tanenbaum, Thijn R. Brummelkamp, Daniel Durocher, Marcel A.T.M. van Vugt   +22 more
doaj   +1 more source

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRASG12C-mutant lung cancer

Cell Death and Disease
The clinical effect of KRAS G12C inhibitors (G12Ci) as monotherapy is poor, prompting the development of combination treatment strategies. Here, we demonstrate that the WEE1 kinase inhibitor (WEE1i), Adavosertib, can sensitize the effect of G12Ci through
Chao Zhou, Yuqing Liu, Hongyu Liu, Jun Lu, Bo Zhang, Liang Zhu, Shuyuan Wang, Huimin Lei, Baohui Han   +8 more
doaj   +1 more source

High WEE1 expression is independently linked to poor survival in multiple myeloma

Blood Cancer Journal
Current prognostic scores in multiple myeloma (MM) currently rely on disease burden and a limited set of genomic alterations. Some studies have suggested gene expression panels may predict clinical outcomes, but none are presently utilized in clinical ...
Anish K. Simhal, Ross S. Firestone, Jung Hun Oh, Viswatej Avutu, Larry Norton, Malin Hultcrantz, Saad Z. Usmani, Kylee H. Maclachlan, Joseph O. Deasy   +8 more
doaj   +1 more source

The ATR-WEE1 kinase module inhibits the MAC complex to regulate replication stress response. [PDF]

Nucleic Acids Res, 2021
Wang L, Zhan L, Zhao Y, Huang Y, Wu C, Pan T, Qin Q, Xu Y, Deng Z, Li J, Hu H, Xue S, Yan S.   +12 more
europepmc   +1 more source

Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors. [PDF]

Front Oncol, 2022
Mancini M, De Santis S, Monaldi C, Castagnetti F, Lonetti A, Bruno S, Dan E, Sinigaglia B, Rosti G, Cavo M, Gugliotta G, Soverini S.   +11 more
europepmc   +1 more source

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. [PDF]

Neurooncol Adv, 2022
Mueller S, Cooney T, Yang X, Pal S, Ermoian R, Gajjar A, Liu X, Prem K, Minard CG, Reid JM, Nelson M, Haas-Kogan D, Fox E, Weigel BJ.   +13 more
europepmc   +1 more source